{"entity":{"id":"paper-reiss-rucaparib-maintenance-brca-palb2-pancreatic-jco-2021","kind":"paper","name":"Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2","aka":[],"tldr":"Rucaparib maintenance after platinum chemotherapy kept 60% of 42 patients progression-free at six months, with responses in germline BRCA2, germline PALB2 and somatic BRCA2 carriers, widening the group PARP inhibitors may help beyond POLO's germline BRCA rule.","summary":"Investigator-initiated single-arm phase 2: advanced pancreatic cancer with a germline or somatic pathogenic variant in BRCA1, BRCA2 or PALB2 after at least 16 weeks of platinum without resistance; chemotherapy stopped and rucaparib 600 mg twice daily given until progression. Of 46 enrolled, 42 were evaluable (27 gBRCA2, 7 gBRCA1, 6 gPALB2, 2 sBRCA2). Progression-free survival at 6 months was 59.5%, median 13.1 months; median overall survival 23.5 months; 12-month progression-free survival 54.8%. Response in 36 measurable patients was 41.7% (3 complete), disease control 66.7%, median duration 17.3 months; responses in gBRCA2 (11 of 27), gPALB2 (3 of 6) and sBRCA2 (1 of 2).","asOf":"2026-09-24","links":[{"label":"Reiss et al., J Clin Oncol 2021: maintenance rucaparib in 42 BRCA1, BRCA2 or PALB2 patients","url":"https://doi.org/10.1200/JCO.21.00003"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/33970687/"}],"tags":[],"related":["brca-germline","brca-somatic"],"cancers":["pancreatic","brca-palb2-pdac","metastatic-pdac"],"sections":[],"technologies":[],"targets":["brca","palb2"],"drugs":["rucaparib"],"companies":[],"institutions":["penn-abramson"],"pathways":[],"terms":["synthetic-lethality","germline-vs-somatic"],"trials":[],"people":["robert-vonderheide"],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2021,"doi":"10.1200/JCO.21.00003","pmid":"33970687","authors":"Reiss KA, Mick R, O'Hara MH, et al.","paperType":"rct","findings":["Six-month progression-free survival 59.5%, median 13.1 months; overall survival 23.5 months.","Response 41.7%; gPALB2 3 of 6 and sBRCA2 1 of 2 responded."],"whatItMeans":"It is the evidence that PALB2 and somatic BRCA2 belong in the PARP inhibitor conversation even though the olaparib label stops at germline BRCA.","caveats":["Single-arm, 42 evaluable, platinum-sensitive selection.","Rucaparib has no pancreatic approval."],"changedPractice":false,"participants":46},"route":"/key-papers/paper-reiss-rucaparib-maintenance-brca-palb2-pancreatic-jco-2021/","neighbours":{"biomarker":[{"id":"brca-germline","kind":"biomarker","name":"Germline BRCA1/2 pathogenic variant (gBRCAm)","route":"/biomarkers/brca-germline/"},{"id":"brca-somatic","kind":"biomarker","name":"Tumour (somatic or germline) BRCA1/2 mutation and HRR gene alterations","route":"/biomarkers/brca-somatic/"}],"cancer":[{"id":"brca-palb2-pdac","kind":"cancer","name":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","route":"/cancers/brca-palb2-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"},{"id":"palb2","kind":"target","name":"PALB2","route":"/targets/palb2/"}],"drug":[{"id":"rucaparib","kind":"drug","name":"Rucaparib","route":"/drugs/rucaparib/"}],"institution":[{"id":"penn-abramson","kind":"institution","name":"Abramson Cancer Center, University of Pennsylvania","route":"/institutions/penn-abramson/"}],"term":[{"id":"germline-vs-somatic","kind":"term","name":"Germline vs somatic mutations","route":"/terms/germline-vs-somatic/"},{"id":"synthetic-lethality","kind":"term","name":"Synthetic lethality","route":"/terms/synthetic-lethality/"}],"person":[{"id":"robert-vonderheide","kind":"person","name":"Robert H. Vonderheide","route":"/people/robert-vonderheide/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}